ART closes $6M private placement

ART Advanced Research Technologies, a Canadian medical device company, has closed its previously announced private placement of preferred shares for total proceeds of $6 million to OppenheimerFunds and other long-time shareholders of ART.

The Montreal-based company said it has obtained all necessary approvals to close the private placement, including that of the Toronto Stock Exchange, and intends to use the net proceeds of the financing as working capital.

A total of 46.1 million preferred shares were issued under the private placement at a price of $.13 (Canadian) per preferred share.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.